do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline for type 2 diabetes management Clinical Use of DPP-4 Inhibitors
Description
doi:10.1007/S10384-018-00645-4 17

In India, 90% of type 2 diabetes cases are attributable in part to excess weight or obesity

Science News discussed open questions in the field with Hursting, Ligibel and health data scientist Jiang Bian of the Indiana University School of Medicine in Indianapolis

Human studies examining circulating METRNL levels have produced heterogeneous results, reflecting differences in metabolic state, physical activity, and assay methodology
Assessment of cardiometabolic risk, liver health, and potential contraindications

Regul Pept 2005;125:173177
